Table 2.
Incidencea of Opioid-Induced Hypogonadism Outcomes in Short-term vs Prolonged Opioid Users
| Brief opioid exposure | Short-term opioid use, absolute risk, % (95% CI) | Prolonged opioid use, absolute risk, % (95% CI) |
|---|---|---|
| Serum testosterone test | ||
| 1 year | 3.73 (3.57-3.91) | 5.76 (5.56-5.97) |
| 3 years | 8.94 (8.64-9.27) | 13.60 (13.25-13.96) |
| 5 years | 11.55 (11.11-12.01) | 17.15 (16.70-17.61) |
| Hypogonadism diagnosis | ||
| 1 year | 1.42 (1.32-1.53) | 2.62 (2.49-2.77) |
| 3 years | 3.59 (3.39-3.80) | 7.18 (6.92-7.46) |
| 5 years | 4.85 (4.55-5.16) | 9.44 (9.09-9.80) |
| Testosterone therapy | ||
| 1 year | 0.61 (0.54-0.68) | 1.50 (1.40-1.62) |
| 3 years | 1.65 (1.52-1.80) | 4.55 (4.34-4.77) |
| 5 years | 2.21 (2.04-2.43) | 5.76 (5.49-6.05) |
a
Based on Kaplan-Meier estimates.